×
×

Hereditary Cancer

Color: A Revolution in Hereditary Cancer Genetic Testing

  • Jul 11, 2016

Genetic testing for hereditary cancer: High quality, affordable to all!

Karyo announces the arrival of Color in our region! Color is a 30 gene panel, including BRCA1 and BRCA2, to assist women and men understand their risk for the most common hereditary cancers, including breast, ovarian, colorectal, and pancreatic cancer. and others. Color revolutionizes genetic testing with a series of characteristics:


Color

Ο Γενετικός Έλεγχος Κληρονομούμενου Καρκίνου Color

Ανακαλύψτε εάν διαθέτετε γενετική προδιάθεση για εμφάνιση των συχνότερων μορφών κληρονομικού καρκίνου.

Το γενετικό τεστ Color αναλύει 30 γονίδια – συμπεριλαμβανομένων των BRCA1 και BRCA2 – και βοηθάει γυναίκες και άνδρες να ανακαλύψουν εάν διατρέχουν σημαντικό κίνδυνο εμφάνισης των συχνότερων μορφών κληρονομικού καρκίνου, όπως ο καρκίνος του μαστού, των ωοθηκών, του παχέος εντέρου, του παγκρέατος κ.α.

Επιλέγοντας το Color

myRISK - Myriad

Myriad myRisk Hereditary Cancer is a scientific advancement revolutionizing hereditary cancer testing. Blending both genetic test status AND personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing. Myriad myRisk identifies elevated risk for 8 important cancers by analyzing multiple, clinically significant genes. Additionally, Myriad myRisk provides a summary of available medical society guidelines to help you optimize your patients’ medical management.

BRACAnalysis CDx - Myriad

BRACAnalysis CDx™ (FDA approved BRCA1/2 test) is the companion diagnostic test intended to be used as an aid in treatment decision making for Lynparza™ (olaparib).1

 

Familial Breast / Ovarian Cancer Gene Panel (19 genes)

In about 15-20% of all breast cancer cases, patients present family history but are free of BRCA1 and BRCA2 genetic alterations. In this case, their cancer is termed familial. Recent research has revealed a number mutations in other genes, some rarely mutated but with high-penetrance and other more commonly mutated with individual low-penetrance but cumulative action, that increase the life time risk for developing breast cancer.

BRAF mutation analysis

General:

BRAF belongs to a family of serine-threonine protein kinases that includes ARAF, BRAF, and CRAF (RAF1). RAF kinases are central mediators in the MAP kinase signaling cascade and exert their effect predominantly through phosphorylation and activation of MEK. This occurs following the dimerization (hetero- or homo-) of the RAF molecules. As part of the MAP kinase pathway, RAF is involved in many cellular processes, including cell proliferation, differentiation, and transcriptional regulation.

Color's technical specifications

  • Jul 11, 2014

The Color Test analyzes the most relevant genes for mutations that could increase your patient’s risk for hereditary

  • breast
  • colorectal
  • melanoma
  • ovarian
  • pancreatic
  • prostate
  • stomach, and
  • uterine cancers

The genes analyzed are:

APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A (p14ARF), CDKN2A (p16INK4a), CHEK2, EPCAM, GREM1, MITF, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11 and TP53.


PANEXIA - Myriad

PANEXIA®: Hereditary Testing for Pancreatic Cancer

PANEXIA® is a genetic test specifically created to detect mutations in genes that result in an increased risk of pancreatic cancer, offering insight about the risk of future hereditary cancers for patients and their families. PANEXIA, via a simple blood test, analyzes the PALB2 and BRCA2 genes, the two genes most commonly identified in families with hereditary pancreatic cancer.

MELARIS - Myriad

MELARIS®: Hereditary Cancer Testing for Melanoma

MELARIS® testing assesses a person’s risk of developing hereditary melanoma. This test detects inherited mutations in the p16 gene (also called CDKN2A or INK4A), which are associated with hereditary melanoma and hereditary pancreatic cancer.

If your patient has a family history of cancer, the disease may come from an inherited genetic change. Changes in the p16 gene increase cancer risk, making a melanoma diagnosis up to 50 times more likely by age 50.

Pages